Best Value Is More Than the Lowest Price

Federal medical device procurements are not always decided by comparing unit prices and selecting the lowest number. The Federal Acquisition Regulation defines “best value” as the outcome expected to provide the Government with the greatest overall benefit. In negotiated acquisitions, agencies may use different source-selection approaches depending on the requirement, performance risk, and importance of price relative to non-price considerations.

Best Value Tradeoff and LPTA Are Different Evaluation Methods

Under a Best Value Tradeoff process, the Government may select a higher-priced proposal when documented clinical, operational, and financial benefits justify the additional cost.

Under a Lowest-Price Technically Acceptable (LPTA) process, no such tradeoff occurs: proposals are assessed solely against minimum technical requirements, and the award goes to the lowest-priced acceptable offer.

Identifying the evaluation method early dictates whether a manufacturer should position on price or on broader system value.

Non-Price Factors Can Extend Beyond Product Specifications

For medical devices and clinical technologies, non-price evaluation criteria frequently encompass both direct product specifications and broader healthcare delivery impacts:

• Clinical Outcomes & Patient Safety: Superior clinical efficacy, reduced complication or readmission rates, faster recovery times, and improved patient health outcomes.
• Site-of-Care Optimization: Capability to safely shift procedures from high-cost inpatient settings to lower-cost outpatient or ambulatory care environments.
• Physician & Staff Workflow Efficiency: Measurable time savings for clinical staff, streamlined procedural steps, intuitive ease of use, reduced operator fatigue, and lower training burdens.
• Total Cost of Care & Lifecycle Savings: Long-term financial value that offsets acquisition costs through downstream system savings—such as reduced facility time, minimized downtime, fewer post-procedure interventions, and efficient use of consumables, accessories, and maintenance.
• Operational & Technical Support: Implementation risk, IT and cybersecurity compliance, software support, supply chain continuity, field service reliability, and past performance.

Federal acquisition planning explicitly accounts for these holistic tradeoffs—weighing technical merit, clinical performance, total lifecycle and operational costs, logistics, and risk to secure solutions that deliver optimal value to federal health systems.

Value Must Be Connected to the Solicitation

These differentiators matter only when they are tied to what the agency has asked offerors to address. Federal evaluators must assess proposals against the factors and significant subfactors stated in the solicitation, including their relative importance.

As a result, a technically superior feature may receive little or no evaluation credit if the proposal does not connect it to a stated requirement, evaluation factor, performance risk, or cost consideration.

Proposal Strategy Should Begin With a Structured Review

Proposal strategy should therefore begin with a structured review of the solicitation. The team should distinguish mandatory requirements from evaluated strengths, pass/fail criteria from tradeoff factors, and proposal instructions from contract-performance obligations.

It should also determine whether supporting evidence is required, such as clinical data, technical documentation, delivery plans, training materials, cybersecurity information, warranty terms, past-performance references, or supply-chain commitments.

A Better Product Does Not Automatically Justify a Premium Price

A premium price is not automatically justified by a better product. The proposal must connect each claimed advantage to the agency’s stated need, evaluation criteria, performance risk, or total cost.

Unsupported marketing language, unrequested features, and generic claims of superiority are less persuasive than specific, solicitation-responsive evidence. Any award decision and price-versus-benefit tradeoff must ultimately be grounded in the source-selection criteria stated in the solicitation.